High postprandial triglyceridemia in patients with type 2 diabetes and microalbuminuria

Journal of Lipid Research

Volumn 48, Issue 1, 2007, Pages 218-225

  Tentolouris, Nicholas ^a   Stylianou, Andreas ^a   Lourida, Evangelia ^b   Perrea, Despoina ^a   Kyriaki, Despoina ^a   Papavasiliou, Eleni C ^b   Tselepis, Alexandros D ^b   Katsilambros, Nicholas ^a  

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^b UNIVERSITY OF IOANNINA   (Greece)

Author keywords

Apolipoprotein A V; Apolipoprotein C II; Apolipoprotein C III; Hepatic lipase; Lipoprotein lipase; Postprandial lipemia; Triglycerides

Indexed keywords

ANTIDIABETIC AGENT; APOLIPOPROTEIN A5; APOLIPOPROTEIN C2; APOLIPOPROTEIN C3; CHYLOMICRON; INSULIN;

ADULT; AGED; ARTICLE; CARDIOVASCULAR RISK; CONTROLLED STUDY; DIET RESTRICTION; DIET THERAPY; DISEASE ASSOCIATION; FEMALE; HUMAN; HYPERLIPIDEMIA; HYPERTRIGLYCERIDEMIA; MAJOR CLINICAL STUDY; MALE; MEAL; MICROALBUMINURIA; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RISK FACTOR; TABLET FORMULATION; TRIACYLGLYCEROL BLOOD LEVEL;

AGED; ALBUMINURIA; BLOOD PRESSURE; BODY SIZE; CHYLOMICRONS; DIABETES MELLITUS, TYPE 2; FEMALE; GLOMERULAR FILTRATION RATE; HUMANS; HYPERTRIGLYCERIDEMIA; HYPOGLYCEMIC AGENTS; LIPOPROTEIN LIPASE; LIPOPROTEINS, HDL; MALE; MIDDLE AGED; POSTPRANDIAL PERIOD; TRIGLYCERIDES;

EID: 33845994707     PISSN: 00222275     EISSN: 15397262     Source Type: Journal    
DOI: 10.1194/jlr.M600367-JLR200     Document Type: Article

References (39)

1. Stamler, J., O. Vaccaro, J. D. Neaton, and D. Wentworth. 1993. Diabetes, other risk factors, and 12-yr cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial. Diabetes Care. 16: 434-444.
2. Schmitz, A., and M. Vaeth. 1988. Microalbuminuria: a major risk factor in non-insulin-dependent diabetes. A 10-year follow-up study of 503 patients. Diabet. Med. 5: 126-134.
3. Dinneen, S. F., and H. C. Gerstein. 1997. The association of microalbuminuria and mortality in non-insulin-dependent diabetes mellitus. A systematic review of the literature. Arch. Intern. Med. 157: 1413-1418.
4. MacIsaac, R. J., and M. E. Cooper. 2003. Microalbuminuria and diabetic cardiovascular disease. Curr. Atheroscler. Rep. 5: 350-357.
5. Syvanne, M., and M. R. Taskinen. 1997. Lipids and lipoproteins as coronary risk factors in non-insulin dependent diabetes mellitus. Lancet. 350 (Suppl. 1): 20-23.
6. Betteridge, D. J. 1999. Diabetic dyslipidaemia. Eur. J. Clin. Invest. 29 (Suppl. 2): 12-16.
7. Katsilambros, N. 1995. Postprandial triglyceridaemia. Diabet. Med. 12: 451-452.
8. De Man, F. H., M. C. Cabezas, H. H. Van Barlingen, D. W. Erkelens, and T. W. de Bruin. 1996. Triglyceride-rich lipoproteins in non-insulin-dependent diabetes mellitus: post-prandial metabolism and relation to premature atherosclerosis. Eur. J. Clin. Invest. 26: 89-108.
9. Ginsberg, H. N., Y. L. Zhang, and A. Hernandez-Ono. 2005. Regulation of plasma triglycerides in insulin resistance and diabetes. Arch. Med. Res. 36: 232-240.
10. Boquist, S., G. Ruotolo, R. Tang, J. Bjorkegren, M. G. Bond, U. de Faire, F. Karpe, and A. Hamsten. 1999. Alimentary lipemia, post-prandial triglyceride-rich lipoproteins, and common carotid intima-media thickness in healthy, middle-aged men. Circulation. 100: 723-728.
11. Fontbonne, A., E. Eschwege, F. Cambien, J. L. Richard, P. Ducimetiere, N. Thibult, J. M. Warnet, J. R. Claude, and G. E. Rosselin. 1989. Hypertriglyceridaemia as a risk factor of coronary heart disease mortality in subjects with impaired glucose tolerance or diabetes. Results from the 11-year follow-up of the Paris Prospective Study. Diabetologia. 32: 300-304.
12. Otarod, J. K., and I. J. Goldberg. 2004. Lipoprotein lipase and its role in regulation of plasma lipoproteins and cardiac risk. Curr. Atheroscler. Rep. 6: 335-342.
13. Kashiwazaki, K., T. Hirano, G. Yoshino, M. Kurokawa, H. Tajima, and M. Adachi. 1998. Decreased release of lipoprotein lipase is associated with vascular endothelial damage in NIDDM patients with microalbuminuria. Diabetes Care. 21: 2016-2020.
14. Groot, P. H., W. A. van Stiphout, X. H. Krauss, H. Jansen, A. van Tol, E. van Ramshorst, S. Chin-On, A. Hofman, S. R. Cresswell, and L. Havekes. 1996. Multiple lipoprotein abnormalities in type 1 diabetic patients with renal disease. Diabetes. 45: 974-979.
15. Kahri, J., P. H. Groop, T. Elliott, G. Viberti, and M. R. Taskinen. 1994. Plasma cholesterol ester transfer protein and its relationship to plasma lipoproteins and apolipoprotein A-I-containing lipoproteins in IDDM patients with microalbuminuria and clinical nephropathy. Diabetes Care. 17: 412-419.
16. Nagashima, K., C. Lopez, D. Donovan, C. Ngai, N. Fontanez, A. Bensadoun, J. Fruchart-Najib, S. Holleran, J. S. Cohn, R. Ramakrishnan, et al. 2005. Effects of PPARg agonist pioglitazone on lipoprotein metabolism in patients with type 2 diabetes mellitus. J. Clin. Invest. 115: 1323-1332.
17. Hirano, T. 1999. Lipoprotein abnormalities in diabetic nephropathy. Kidney Int. 71 (Suppl.): 22-24.
18. Beauchamp, M. C., E. Letendre, and G. Renier. 2002. Macrophage lipoprotein lipase expression is increased in patients with heterozygous familial hypercholesterolemia. J. Lipid Res. 43: 215-222.
19. Tentolouris, N., M. Kolia, A. D. Tselepis, D. Perea, E. Kitsou, D. Kyriaki, A. P. Tambaki, S. P. Karabina, C. Sala, E. Fragoulopoulos, et al. 2003. Lack of effect of acute repaglinide administration on postprandial lipaemia in patients with type 2 diabetes mellitus. Exp. Clin. Endocrinol. Diabetes. 111: 370-373.
20. O'Brien, P. J., W. E. Alborn, J. H. Sloan, M. Ulmer, A. Boodhoo, M. D. Knierman, A. E. Schultze, and R. J. Konrad. 2005. The novel apolipoprotein A5 is present in human serum, is associated with VLDL, HDL, and chylomicrons, and circulates at very low concentrations compared with other apolipoproteins. Clin. Chem. 51: 351-359.
21. Friedewald, W. T., R. I. Levy, and D. S. Fredrickson. 1972. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin. Chem. 18: 499-502.
22. Cockcroft, D., and M. H. Gault. 1976. Prediction of creatinine clearance from serum creatinine. Nephron. 16: 31-41.
23. Matthews, D. R., J. P. Hosker, A. S. Rudenski, B. A. Naylor, D. F. Treacher, and R. C. Turner. 1985. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia. 28: 412-419.
24. Expert Panel. 2001. Executive summary of the third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). J. Am. Med. Assoc. 285: 2486-2497.
25. Nordestgaard, B. G., R. Wootton, and B. Lewis. 1995. Selective retention of VLDL, IDL, and LDL in the arterial intima of genetically hyperlipidemic rabbits in vivo. Molecular size as a determinant of fractional loss from the intima-inner media. Arterioscler. Thromb. Vasc. Biol. 15: 534-542.
26. Miller, G. J. 1998. Postprandial lipaemia and haemostatic factors. Atherosclerosis. 141 (Suppl. 1): 47-51.
27. Deckert, T., B. Feldt-Rasmussen, K. Borch-Johnsen, T. Jensen, and A. Kofoed-Enevoldsen. 1989. Albuminuria reflects widespread vascular damage. The Steno hypothesis. Diabetologia. 32: 219-226.
28. Hansen, P. M., T. Jensen, J. Egeberg, H. Lithell, A. Kofoed-Enevoldsen, and T. Deckert. 1997. Skeletal muscle lipoproteinlipase activity in insulin-dependent diabetic patients with and without albuminuria. J. Diabetes Complications. 11: 230-235.
29. Jansen, H. 2004. Hepatic lipase: friend or foe and under what circumstances? Curr. Atheroscler. Rep. 6: 343-346.
30. Santamarina-Fojo, S., and K. A. Dugi. 1994. Structure, function and role of lipoprotein lipase in lipoprotein metabolism. Curr. Opin. Lipidol. 5: 117-125.
31. Tan, K. C., M. B. Cooper, K. L. Ling, B. A. Griffin, D. J. Freeman, C. J. Packard, J. Shepherd, C. N. Hales, and D. J. Betteridge. 1995. Fasting and postprandial determinants for the occurrence of small dense LDL species in non-insulin-dependent diabetic patients without hypertriglyceridaemia: the involvement of insulin, insulin precursor species and insulin resistance. Atherosclerosis. 113: 273-287.
32. Desmeules, A., C. Couillard, A. Tchernof, J. Bergeron, T. Rankinen, A. S. Leon, D. C. Rao, J. S. Skinner, J. H. Wilmore, J. P. Despres, et al. 2003. Post-heparin lipolytic enzyme activities, sex hormones and sex hormone-binding globulin (SHBG) in men and women: the HERITAGE Family Study. Atherosclerosis. 171: 343-350.
33. Dallinga-Thie, G. M., I. I. Berk-Planken, A. H. Bootsma, and H. Jansen, for the Diabetes Atorvastatin Lipid Intervention (DALI) Study Group. 2004. Atorvastatin decreases apolipoprotein C-III in apolipoprotein B-containing lipoprotein and HDL in type 2 diabetes: a potential mechanism to lower plasma triglycerides. Diabetes Care. 27: 1358-1364.
34. Batal, R., M. Tremblay, P. H. Barrett, H. Jacques, A. Fredenrich, O. Mamer, J. Davignon, and J. S. Cohn. 2000. Plasma kinetics of apoC-III and apoE in normolipidemic and hypertriglyceridemic subjects. J. Lipid Res. 41: 706-718.
35. Kosuge, K., T. Miida, A. Takahashi, K. Obayashi, M. Ito, T. Ito, S. Soda, K. Ozaki, S. Hirayama, O. Hanyu, et al. 2006. Estimating the fasting triglyceride concentration from the postprandial HDL-cholesterol and apolipoprotein CIII concentrations. Atherosclerosis. 184: 413-419.
36. Attia, N., V. Durlach, M. Cambilleau, D. Roche, and A. Girard-Globa. 2000. Postprandial concentrations and distribution of apo C-III in type 2 diabetic patients. Effect of bezafibrate treatment. Atherosclerosis. 149: 427-433.
37. Federico, L. M., M. Naples, D. Taylor, and K. Adeli. 2006. Intestinal insulin resistance and aberrant production of apolipoprotein B48 lipoproteins in an animal model of insulin resistance and metabolic dyslipidemia: evidence for activation of protein tyrosine phosphatase-1B, extracellular signal-related kinase, and sterol regulatory element-binding protein-1c in the fructose-fed hamster intestine. Diabetes. 55: 1316-1326.
38. Alberti, K. G., and P. Z. Zimmet. 1998. Definition, diagnosis and classification of diabetes mellitus and its complications. I. Diagnosis and classification of diabetes mellitus. Provisional report of a WHO consultation. Diabet. Med. 15: 539-553.
39. Mattu, R. K., J. Trevelyan, E. W. Needham, M. Khan, M. A. Adiseshiah, D. Richter, R. G. Murray, and D. J. Betteridge. 2004. Lipoprotein lipase gene variants relate to presence and degree of microalbuminuria in type II diabetes. Diabetologia. 45: 905-913.